EMA Committee Recommends Approval for Rare Neurodegenerative Disease Drug

The European Medicines Agency's CHMP has issued a positive opinion for marketing authorization of Nezglyal (leriglitazone) to treat Cerebral Adrenoleukodystrophy (cALD) in males aged 2 to 12 years. This rare and debilitating neurodegenerative disease currently lacks approved pharmacological treatments in the EU. European Commission approval is expected by late September 2026, offering a new therapeutic option for affected children.